Concert Pharmaceuticals - 股票

Concert Pharmaceuticals 股本 2024

Concert Pharmaceuticals 股本

112.22 百万 USD

股票代码

CNCE

ISIN

US2060221056

WKN

A1XEAC

在2024年,Concert Pharmaceuticals的股本为112.22 百万 USD,比上一年的0 USD资本增长了0%

Concert Pharmaceuticals Aktienanalyse

Concert Pharmaceuticals在做什么?

Concert Pharmaceuticals Inc was founded in 2006 and is based in Lexington, Massachusetts. The company is engaged in the discovery and development of innovative drugs for the treatment of serious diseases. The goal is to explore and bring to market novel therapeutic approaches to help people with medical needs. The company has a unique business model that focuses on the use of patented deuterosome technologies and other proprietary methods. These technologies allow Concert Pharmaceuticals to modify and alter the properties of existing drugs. This enables the development of new products that either have higher efficacy or produce fewer adverse effects in patients. One of Concert Pharmaceuticals' key areas is neurological disorders. Here, the company focuses its research on the treatment of diseases such as Alzheimer's, schizophrenia, depression, and pain. In addition, Concert Pharmaceuticals also has projects in other areas, such as the treatment of respiratory diseases, cancer, or metabolic disorders. One of the best-known products of Concert Pharmaceuticals is the drug CTP-543 for the treatment of alopecia areata or patchy hair loss. The condition, which causes sudden and massive hair loss, can be very distressing and poses a major challenge, as there is currently no effective treatment method known. CTP-543 was designated as an orphan drug by the FDA (Food and Drug Administration) in the United States in 2020. This means that it is a drug that is used to treat a rare disease and is financially supported by the FDA. The company hopes that the medication will soon be available on the market and can help those affected to improve their quality of life. Concert Pharmaceuticals also has a collaboration with Celgene Corporation, an internationally active biotechnology company. Together, they aim to develop drugs that can help in the treatment of cancer. This collaboration is intended to accelerate scientific and technological advancements. The goal is to help patients faster and more effectively. Overall, Concert Pharmaceuticals employs around 120 people and has a number of patents and scientific publications to its name in recent years. The company collaborates with many renowned institutions and research facilities worldwide to find the best possible solutions in drug development. In summary, Concert Pharmaceuticals Inc is a very innovative company in the field of drug development. In addition to neurological research, the company also has projects in other areas. With its unique business model and the use of patented technologies, Concert Pharmaceuticals has the potential to develop new and effective drugs in the future, thereby improving the lives of many people worldwide. Concert Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

股本的详细信息

Concert Pharmaceuticals的股本分析

Concert Pharmaceuticals的股本代表了公司的所有者权益,是总资产与总负债之间的差额。它反映了在所有债务都得到偿还之后,股东对公司资产的剩余权益。理解Concert Pharmaceuticals的股本对评估其财务健康,稳定性以及对股东的价值至关重要。

年对年比较

评估Concert Pharmaceuticals连续几年的股本,可以提供有关公司的增长,盈利能力以及资本结构的观点。股本的增长表明净资产和财务健康的改善,而股本的减少可能表明债务的增加或运营上的挑战。

对投资的影响

Concert Pharmaceuticals的股本对投资人来说是一个关键的元素,它影响了公司的杠杆,风险档案以及股本回报率(ROE)。较高的股本水平通常预示着较低的风险和增加的财务稳定性,使得公司可能成为有吸引力的投资机会。

解读股本波动

Concert Pharmaceuticals的股本波动可能源于各种因素,包括净利润的变动,分红,以及发行或回购股票。投资人分析这些变化,以评估公司的财务表现,运营效率和战略财务管理。

关于Concert Pharmaceuticals股票的常见问题

Concert Pharmaceuticals今年的股本是多少?

Concert Pharmaceuticals今年的股本为112.22 百万 USD。

Concert Pharmaceuticals的股本与去年相比高了多少?

Concert Pharmaceuticals的股本与去年相比,0下降了。

Concert Pharmaceuticals的投资者高额的股本会产生什么影响?

对于Concert Pharmaceuticals的投资者来说,高额的股本是有利的,因为它是公司财务稳定性的指标,展示了公司应对风险和挑战的能力。

Concert Pharmaceuticals的投资者低资本充足率会有什么影响?

对于Concert Pharmaceuticals的投资者来说,较低的自有资本可能构成风险,因为这会使公司处于较弱的财务地位,并可能影响其应对风险和挑战的能力。

Concert Pharmaceuticals的股本增加对公司有什么影响?

增加Concert Pharmaceuticals的股本可以强化公司的财务状况,提高其未来投资的能力。

Concert Pharmaceuticals的股本减少会如何影响公司?

Concert Pharmaceuticals的股本减少可能会影响公司的财务状况,并导致对债务资金的依赖度增加。

什么因素会影响Concert Pharmaceuticals的股本?

一些可能影响Concert Pharmaceuticals股本的因素包括利润,股息支付,增资和收购。

为什么Concert Pharmaceuticals的股本对投资者如此重要?

Concert Pharmaceuticals的股本对投资者非常重要,因为它是公司财务实力的指标,也可能是该公司有能力履行其财务义务的迹象。

Concert Pharmaceuticals可以采取哪些战略措施来改变自己的股本?

为了改变自身的股本,Concert Pharmaceuticals可以采取包括提高利润,实施增资,减少开支和收购企业等多种措施。对公司来说,彻底检查其财务状况以确定最佳的策略性措施来改变其股本的情况非常重要。

Concert Pharmaceuticals支付多少股息?

在过去的12个月中,Concert Pharmaceuticals支付了 的股息。这相当于大约的股息收益率。在未来的12个月内,Concert Pharmaceuticals预计将支付0 USD的股息。

Concert Pharmaceuticals的股息收益率有多高?

Concert Pharmaceuticals当前的股息收益率为。

Concert Pharmaceuticals什么时候支付股息?

Concert Pharmaceuticals按季度支付股息。这些股息将在月份分发。

Concert Pharmaceuticals的股息有多安全?

Concert Pharmaceuticals 在过去0年里每年都支付了股息。

Concert Pharmaceuticals的股息有多高?

预计未来12个月的股息将达到0 USD。这相当于0 %的股息收益率。

Concert Pharmaceuticals位于哪个行业?

Concert Pharmaceuticals 被分配到“健康”板块。

Wann musste ich die Aktien von Concert Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

要获得Concert Pharmaceuticals在支付的0 USD的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Concert Pharmaceuticals最后一次支付股息是什么时候?

上一次股息发放日期为。

Concert Pharmaceuticals在2023年的股息是多少?

在2023年,Concert Pharmaceuticals 分配了0 USD作为股息。

Concert Pharmaceuticals 的股息是以哪种货币支付的?

Concert Pharmaceuticals的股息将以USD的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Andere Kennzahlen von Concert Pharmaceuticals

我们对Concert Pharmaceuticals 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Concert Pharmaceuticals 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: